February 18, 2009
Including genetic information in a patient’s clinical profile might help determine the optimal starting dose of the common blood-thinner warfarin, according to findings from a large-scale study that will be published tomorrow, Thursday, February 19, in the New England Journal of Medicine.
UW’s campaign to restore the ASUW Shell House exceeds goal, showcases community support 8 hours ago
Virtual reality environment for teens may offer an accessible, affordable way to reduce stress 14 hours ago
Scientists solve chemical mystery at the interface of biology and technology 2 days ago